Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
70,909,094
-
Share change
-
-6,941,003
-
Total reported value
-
$44,669,856
-
Put/Call ratio
-
2.7%
-
Price per share
-
$0.63
-
Number of holders
-
106
-
Value change
-
-$6,711,720
-
Number of buys
-
30
-
Number of sells
-
43
Institutional Holders of ZIOPHARM ONCOLOGY INC - COM (TCRT) as of Q1 2023
As of 31 Mar 2023,
ZIOPHARM ONCOLOGY INC - COM (TCRT) was held by
106 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
70,909,094 shares.
The largest 10 holders included
DISCOVERY CAPITAL MANAGEMENT, LLC / CT, MSD Partners, L.P., VANGUARD GROUP INC, Laurion Capital Management LP, BlackRock Inc., JPMORGAN CHASE & CO, GEODE CAPITAL MANAGEMENT, LLC, TWO SIGMA ADVISERS, LP, Boxer Capital, LLC, and GSA CAPITAL PARTNERS LLP.
This page lists
106
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.